Cholesterol Lowering and the Use of Healthcare Resources Results of the Scandinavian Simvastatin Survival Study

Circulation

Volumn 93, Issue 10, 1996, Pages 1796-1802

  Pedersen, Terje R ^a   Kjekshus, John ^b   Berg, Kåre ^b   Olsson, Anders G ^b   Wilhelmsen, Lars ^b   Wedel, Hans ^b   Pyörälä, Kalevi ^b   Miettinen, Tatu ^b   Haghfelt, Torben ^b   Færgeman, Ole ^b   Thorgeirsson, Gudmundur ^b   Jönsson, Bengt ^b   Schwartz, J Sanford ^b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Cholesterol; Coronary disease; Drugs; Prevention

Indexed keywords

SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG RESEARCH; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; SURVIVAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEALTH CARE COSTS; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 0029883280     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.10.1796     Document Type: Article

References (25)

1. American Heart Association. Heart and Stroke Facts: 1994 Statistical Supplement. Dallas, Tex: American Heart Association; 1994.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
3. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
5. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, for the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
6. Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. JAMA. 1987; 258:2381-2387.
7. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;259: 2249-2254.
8. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265: 1145-1151.
9. Sønbø Kristiansen I, Eggen AL, Thelle DS. Cost-effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? Br Med J. 1991;302: 1119-1122.
10. Martens LL, Rutten FFH, Erkelens DW, Ascoop CAPL. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol. 1990;65:27F-32F.
11. WHO MONICA Project. MONICA Manual, Revised Edition. Geneva, Switzerland: Cardiovascular Diseases Unit, WHO: 1990.
12. Tuomilehto J, Arstila M, Kaarsalo E, Kankaanpää J, Ketonen M, Kuulasmaa, K, Lehto S, Miettinen H, Mustaniemi H, Palomäki P, Puska P, Pyörälä K, Salomaa V, Torppa J, Vuorenmaa T. Acute myocardial infarction in Finland: baseline data from the FIN-MONICA AMI register in 1983-85. Eur Heart J. 1992;13.577-587.
13. The MEDSAT Groups Inc. DRG Guide: Descriptions and Normative Values. Ann Arbor. Mich; 1994.
14. First Data Bank/Hearst Corp. Wholesale Acquisition Costs of Inhibitors of HMG-CoA Reductase. San Bruno, Calif: Price Probe (4.2); April 24, 1995.
15. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
16. Hochberg Y. A sharper Bonferroni procedure for multiple test of significance. Biometrika. 1988;75:800-802.
17. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr. 1994;48:305-325.
18. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583-612.
19. US Department of Health and Human Services. National Hospital Discharge Survey: Annual Summary, 1991. Vital Health Stat. 1993; series 13.
20. Linger F. European survey on open heart surgery, PTCA and cardiac catheterisation in 1992. Ann Eur Acad Sci Arts. 1993;6: 12-66.
21. Haskell WL, Alderman, EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89: 975-990.
22. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals. 1st ed. Ottawa, Ontario, Canada: November 1994.
23. Pharmaceutical Benefits Advisory Committee, Commonwealth Department of Health, Housing and Community Service. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Australian Government Publishing Service; 1992.
24. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 1994;308:367-372.
25. Gould AL, Rossouw JE, Santanello NC, Heyse J, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282.